BR112022011037A2 - Anticorpos ddr1 novos e usos dos mesmos - Google Patents

Anticorpos ddr1 novos e usos dos mesmos

Info

Publication number
BR112022011037A2
BR112022011037A2 BR112022011037A BR112022011037A BR112022011037A2 BR 112022011037 A2 BR112022011037 A2 BR 112022011037A2 BR 112022011037 A BR112022011037 A BR 112022011037A BR 112022011037 A BR112022011037 A BR 112022011037A BR 112022011037 A2 BR112022011037 A2 BR 112022011037A2
Authority
BR
Brazil
Prior art keywords
ddr1
antibodies
new
present disclosure
ddr1 antibodies
Prior art date
Application number
BR112022011037A
Other languages
English (en)
Inventor
Zhang Ningyan
An Zhiqiang
Deng Hui
Sun Xiujie
Li Rong
Original Assignee
Univ Texas
Univ George Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Univ George Washington filed Critical Univ Texas
Publication of BR112022011037A2 publication Critical patent/BR112022011037A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

ANTICORPOS DDR1 NOVOS E USOS DOS MESMOS. A presente divulgação se refere a anticorpos ligando ao receptor de domínio de discoidina tumoral 1 (DDR1) e aos usos dos anticorpos na detecção e no tratamento de câncer. Assim, em um aspecto, a presente divulgação fornece um anticorpo monoclonal isolado ou um fragmento de ligação a antígeno do mesmo que liga especificamente a DDR1, modula a atividade de DDR1, isto é, suprime DDR1.
BR112022011037A 2019-12-17 2020-12-17 Anticorpos ddr1 novos e usos dos mesmos BR112022011037A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949300P 2019-12-17 2019-12-17
PCT/US2020/065618 WO2021127185A1 (en) 2019-12-17 2020-12-17 Novel ddr1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022011037A2 true BR112022011037A2 (pt) 2022-09-13

Family

ID=76478553

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022011037A BR112022011037A2 (pt) 2019-12-17 2020-12-17 Anticorpos ddr1 novos e usos dos mesmos

Country Status (10)

Country Link
US (2) US20230130372A1 (pt)
EP (1) EP4076526A1 (pt)
JP (1) JP2023508277A (pt)
CN (1) CN115443150A (pt)
AU (1) AU2020407089B2 (pt)
BR (1) BR112022011037A2 (pt)
CA (1) CA3160181A1 (pt)
IL (1) IL294019A (pt)
MX (1) MX2022007353A (pt)
WO (1) WO2021127185A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230130372A1 (en) * 2019-12-17 2023-04-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8652843B2 (en) * 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
WO2013027802A1 (ja) * 2011-08-23 2013-02-28 中外製薬株式会社 抗腫瘍活性を有する新規な抗ｄｄｒ１抗体
WO2018112474A1 (en) * 2016-12-16 2018-06-21 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
US11352432B2 (en) * 2017-03-09 2022-06-07 Mab Discovery Gmbh Antibodies specifically binding to human IL-1R7
EP3642231A4 (en) * 2017-06-22 2021-06-23 Apexigen, Inc. ANTI-VISTA ANTIBODIES AND METHODS OF USE
US20230130372A1 (en) * 2019-12-17 2023-04-27 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3160181A1 (en) 2021-06-24
AU2020407089B2 (en) 2023-06-01
CN115443150A (zh) 2022-12-06
IL294019A (en) 2022-08-01
EP4076526A1 (en) 2022-10-26
WO2021127185A1 (en) 2021-06-24
JP2023508277A (ja) 2023-03-02
MX2022007353A (es) 2022-09-19
AU2020407089A1 (en) 2022-06-30
US20230235078A1 (en) 2023-07-27
US20230130372A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
CY1123884T1 (el) Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
AU2020255712B2 (en) Anti-PD-L1/VEGF bifunctional antibody and use thereof
BR112019002168A2 (pt) anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina
BR112017023849A2 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos
BR112017006825A2 (pt) anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
BR112017009263A2 (pt) anticorpo ou fragmento do mesmo que se liga a uma cd38 humana, anticorpo biespecífico, anticorpo ou fragmento do mesmo que se liga a cd38 humana e de cinomólgos, epítopo sobre a cd38 humana solúvel, composição e imunoconjugado
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112015006060A2 (pt) agentes de ligação kir3dl2
SG170728A1 (en) Anti-tumor cell antigen antibody therapeutics
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
BR112012021941A2 (pt) Proteínas terapêuticas de ligação a dll4
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
BR112022007313A2 (pt) Conjugado de um agente quelante, e, radiofármaco
MX2021010893A (es) Anticuerpo biespecifico enlazado especificamente a vegf y ang2.
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos